Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Donald N. Cook is active.

Publication


Featured researches published by Donald N. Cook.


Nature Neuroscience | 2006

Control of microglial neurotoxicity by the fractalkine receptor

Astrid E. Cardona; Erik P. Pioro; Margaret E. Sasse; Volodymyr Kostenko; Sandra M. Cardona; Ineke M. Dijkstra; De Ren Huang; Grahame J. Kidd; Stephen M. Dombrowski; Ranjan Dutta; Jar Chi Lee; Donald N. Cook; Steffen Jung; Sergio A. Lira; Dan R. Littman; Richard M. Ransohoff

Microglia, the resident inflammatory cells of the CNS, are the only CNS cells that express the fractalkine receptor (CX3CR1). Using three different in vivo models, we show that CX3CR1 deficiency dysregulates microglial responses, resulting in neurotoxicity. Following peripheral lipopolysaccharide injections, Cx3cr1−/− mice showed cell-autonomous microglial neurotoxicity. In a toxic model of Parkinson disease and a transgenic model of amyotrophic lateral sclerosis, Cx3cr1−/− mice showed more extensive neuronal cell loss than Cx3cr1+ littermate controls. Augmenting CX3CR1 signaling may protect against microglial neurotoxicity, whereas CNS penetration by pharmaceutical CX3CR1 antagonists could increase neuronal vulnerability.


Nature Immunology | 2004

Toll-like receptors in the pathogenesis of human disease.

Donald N. Cook; David S. Pisetsky; David A. Schwartz

Members of the Toll-like receptor (TLR) family are key regulators of both innate and adaptive immune responses. The function of TLRs in various human diseases has been investigated by comparison of the incidence of disease among people having different polymorphisms in genes that participate in TLR signaling. These studies have shown that TLR function affects several diseases, including sepsis, immunodeficiencies, atherosclerosis and asthma. As this body of data grows, it will provide new insights into disease pathogenesis as well as valuable information on the merits of various therapeutic options.


Immunity | 2000

CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue.

Donald N. Cook; Dina M. Prosser; Reinhold Förster; Jiwen Zhang; Nelly A. Kuklin; Susan J. Abbondanzo; Xiaoda Niu; Shu-Cheng Chen; Denise Manfra; Maria T. Wiekowski; Lee Sullivan; Sidney R. Smith; Harry B. Greenberg; Satwant K. Narula; Martin Lipp; Sergio A. Lira

Chemokine-directed migration of leukocyte subsets may contribute to the qualitative differences between systemic and mucosal immunity. Here, we demonstrate that in mice lacking the chemokine receptor CCR6, dendritic cells expressing CD11c and CD11b are absent from the subepithelial dome of Peyers patches. These mice also have an impaired humoral immune response to orally administered antigen and to the enteropathic virus rotavirus. In addition, CCR6(-/-) mice have a 2-fold to 15-fold increase in cells of select T lymphocyte populations within the mucosa, including CD4+ and CD8+ alphabeta-TCR T cells. By contrast, systemic immune responses to subcutaneous antigens in CCR6(-/-) mice are normal. These findings demonstrate that CCR6 is a mucosa-specific regulator of humoral immunity and lymphocyte homeostasis in the intestinal mucosa.


Journal of Clinical Investigation | 2001

Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs

Carolyn Foster; Dina M. Prosser; Jacqueline Agans; Ying Zhai; Michelle Smith; Jean E. Lachowicz; Fang L. Zhang; Eric L. Gustafson; Frederick J. Monsma; Maria T. Wiekowski; Susan J. Abbondanzo; Donald N. Cook; Marvin L. Bayne; Sergio A. Lira; Madhu Chintala

ADP plays a critical role in modulating thrombosis and hemostasis. ADP initiates platelet aggregation by simultaneous activation of two G protein-coupled receptors, P2Y1 and P2Y12. Activation of P2Y1 activates phospholipase C and triggers shape change, while P2Y12 couples to Gi to reduce adenylyl cyclase activity. P2Y12 has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel. Recently, we cloned a human orphan receptor, SP1999, highly expressed in brain and platelets, which responded to ADP and had a pharmacological profile similar to that of P2Y12. To determine whether SP1999 is P2Y12, we generated SP1999-null mice. These mice appear normal, but they exhibit highly prolonged bleeding times, and their platelets aggregate poorly in responses to ADP and display a reduced sensitivity to thrombin and collagen. These platelets retain normal shape change and calcium flux in response to ADP but fail to inhibit adenylyl cyclase. In addition, oral clopidogrel does not inhibit aggregation responses to ADP in these mice. These results demonstrate that SP1999 is indeed the elusive receptor, P2Y12. Identification of the target receptor of the thienopyridine drugs affords us a better understanding of platelet function and provides tools that may lead to the discovery of more effective antithrombotic therapies.


Nature Medicine | 2004

Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease

Miriam Merad; Petra Hoffmann; Erik A. Ranheim; Sarah Slaymaker; Markus G. Manz; Sergio A. Lira; Israel F. Charo; Donald N. Cook; Irving L. Weissman; Samuel Strober; Edgar G. Engleman

Skin is the most commonly affected organ in graft-versus-host disease (GVHD). To explore the role of Langerhans cells in GVHD, the principal dendritic cells of the skin, we studied the fate of these cells in mice transplanted with allogeneic bone marrow. In contrast to other dendritic cells, host Langerhans cells were replaced by donor Langerhans cells only when donor T cells were administered along with bone marrow, and the extent of Langerhans cell chimerism correlated with the dose of donor T cells injected. Donor T cells depleted host Langerhans cells through a Fas-dependent pathway and induced the production in skin of CCL20, which was required for the recruitment of donor Langerhans cells. Administration of donor T cells to bone marrow–chimeric mice with persistent host Langerhans cells, but not to mice whose Langerhans cells had been replaced, resulted in marked skin GVHD. These findings indicate a crucial role for donor T cells in host Langerhans cell replacement, and show that host dendritic cells can persist in nonlymphoid tissue for the duration of an animals life and can trigger GVHD despite complete blood chimerism.


American Journal of Respiratory and Critical Care Medicine | 2009

Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness.

Rhonda H. Wilson; Gregory S. Whitehead; Hideki Nakano; Meghan E. Free; Jay K. Kolls; Donald N. Cook

RATIONALE In humans, immune responses to inhaled aeroallergens develop in the lung and draining lymph nodes. Many animal models of asthma bypass this route and instead use intraperitoneal injections of allergen using aluminum hydroxide as an adjuvant. OBJECTIVES We investigated whether allergic sensitization through the airway elicits immune responses qualitatively different than those arising in the peritoneum. METHODS Mice were sensitized to allergen through the airway using low-dose LPS as an adjuvant, or through the peritoneum using aluminum hydroxide as an adjuvant. After a single allergen challenge, ELISA and flow cytometry were used to measure cytokines and leukocyte subsets. Invasive measurements of airway resistance were used to measure allergen-induced airway hyperreactivity (AHR). MEASUREMENTS AND MAIN RESULTS Sensitization through the peritoneum primed strong Th2 responses and eosinophilia, but not AHR, after a single allergen challenge. By contrast, allergic sensitization through the airway primed only modest Th2 responses, but strong Th17 responses. Th17 cells homed to the lung and released IL-17 into the airway on subsequent encounter with inhaled allergen. As a result, these mice developed IL-17-dependent airway neutrophilia and AHR. This AHR was neutrophil-dependent because it was abrogated in CXCR2-deficient mice and also in wild-type mice receiving a neutrophil-depleting antibody. Individually, neither IL-17 nor ongoing Th2 responses were sufficient to confer AHR, but together they acted synergistically to promote neutrophil recruitment, eosinophil recruitment and AHR. CONCLUSIONS Allergic sensitization through the airway primes modest Th2 responses but strong Th17 responses that promote airway neutrophilia and acute AHR. These findings support a causal role for neutrophils in severe asthma.


Nature Immunology | 2005

The chemokine receptor D6 limits the inflammatory response in vivo.

Thomas Jamieson; Donald N. Cook; Robert J. B. Nibbs; Antal Rot; Colin Nixon; Pauline McLean; Antonio Alcami; Sergio A. Lira; Maria T. Wiekowski; Gerard J. Graham

How the inflammatory response is initiated has been well defined but relatively little is known about how such responses are resolved. Here we show that the D6 chemokine receptor is involved in the post-inflammatory clearance of β-chemokines from cutaneous sites. After induction of inflammation by phorbol esters, wild-type mice showed a transient inflammatory response. However, in D6-deficient mice, an excess concentration of residual chemokines caused a notable inflammatory pathology with similarities to human psoriasis. These results suggest that D6 is involved in the resolution of the cutaneous inflammatory response.


Nature Immunology | 2009

Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses

Hideki Nakano; Kaifeng Lisa Lin; Manabu Yanagita; Chantal Charbonneau; Donald N. Cook; Terutaka Kakiuchi; Michael D. Gunn

T helper type 1 (TH1)-polarized immune responses, which confer protection against intracellular pathogens, are thought to be initiated by dendritic cells (DCs) that enter lymph nodes from peripheral tissues. Here we found after viral infection or immunization, inflammatory monocytes were recruited into lymph nodes directly from the blood to become CD11c+CD11bhiGr-1+ inflammatory DCs, which produced abundant interleukin 12p70 and potently stimulated TH1 responses. This monocyte extravasation required the chemokine receptor CCR2 but not the chemokine CCL2 or receptor CCR7. Thus, the accumulation of inflammatory DCs and TH1 responses were much lower in Ccr2−/− mice, were preserved in Ccl2−/− mice and were relatively higher in CCL19–CCL21-Ser–deficient plt mutant mice, in which all other lymph node DC types were fewer in number. We conclude that blood-derived inflammatory DCs are important in the development of TH1 immune responses.


American Journal of Pathology | 2001

Wound Healing in MIP-1α−/− and MCP-1−/− Mice

Quentin E. H. Low; Iulia A. Drugea; Lisa A. Duffner; Daniel Quinn; Donald N. Cook; Barrett J. Rollins; Elizabeth J. Kovacs; Luisa A. DiPietro

A salient feature of normal wound healing is the development and resolution of an acute inflammatory response. Although much is known about the function of inflammatory cells within wounds, little is known about the chemotactic and activation signals that influence this response. As the CC chemokines macrophage inflammatory protein-1α (MIP-1α) and monocyte chemotactic protein-1 (MCP-1) are abundant in acute wounds, wound repair was examined in MIP-1α −/− and MCP-1 −/− mice. Surprisingly, wound re-epithelialization, angiogenesis, and collagen synthesis in MIP-1α −/− mice was nearly identical to wild-type controls. In contrast, MCP-1 −/− mice displayed significantly delayed wound re-epithelialization, with the greatest delay at day 3 after injury (28 ± 5% versus 79 ± 14% re-epithelialization, P −/− mice, with a 48% reduction in capillary density at day 5 after injury. Collagen synthesis was impeded as well, with the wounds of MCP-1 −/− mice containing significantly less hydroxyproline than those of control mice (25 ± 3 versus 50 ± 8 μg/wound at day 5, P −/− mice, suggesting that monocyte recruitment into wounds is independent of this chemokine. The data suggest that MCP-1 plays a critical role in healing wounds, most likely by influencing the effector state of macrophages and other cell types.


Nature Medicine | 2005

CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection

Jeffrey W. Tyner; Osamu Uchida; Naohiro Kajiwara; Edy Y. Kim; Anand C. Patel; Mary P. O'Sullivan; Michael J. Walter; Reto A. Schwendener; Donald N. Cook; Theodore M. Danoff; Michael J. Holtzman

Host defense against viruses probably depends on targeted death of infected host cells and then clearance of cellular corpses by macrophages. For this process to be effective, the macrophage must presumably avoid its own virus-induced death. Here we identify one such mechanism. We show that mice lacking the chemokine Ccl5 are immune compromised to the point of delayed viral clearance, excessive airway inflammation and respiratory death after mouse parainfluenza or human influenza virus infection. Virus-inducible levels of Ccl5 are required to prevent apoptosis of virus-infected mouse macrophages in vivo and mouse and human macrophages ex vivo. The protective effect of Ccl5 requires activation of the Ccr5 chemokine receptor and consequent bilateral activation of Gαi-PI3K-AKT and Gαi-MEK-ERK signaling pathways. The antiapoptotic action of chemokine signaling may therefore allow scavengers to finally stop the host cell-to-cell infectious process.

Collaboration


Dive into the Donald N. Cook's collaboration.

Top Co-Authors

Avatar

Hideki Nakano

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gregory S. Whitehead

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sergio A. Lira

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

David A. Schwartz

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Keiko Nakano

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Rhonda H. Wilson

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Seddon Y. Thomas

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge